The aim of this research is to study the physiological role and the immunotherapeutic potential of the T-cell-derived immunoregulatory lymphokine, T-cell growth factor (TCGF), also known as interleukin-2 (IL-2), and to develop immunoassays for detection of IL-2 in biological fluids or lymphoid cells. To achieve these goals, we have prepared antibodies against: (1) short, chemically-synthesized peptides constructed on the basis of the predicted amino acid sequence of human lL-2; and (2) pure human recombinant IL-2 (rIL-2) made available to us by Amgen. Several antibodies against synthetic IL-2 peptides were found to react with native IL-2 by several criteria, including the high titered and specific reactivity with pure rIL-2 in enzyme-linked immunosorbent assays or immunoblots. Moreover, some of these antibodies specifically stain activated human T-cell cytoplasm and, when immobilized on plastic plates, can bind IL-2 in solution, which indicates their usefulness for developing quantitative IL-2 immunoassays. Polyclonal and monoclonal antibodies were also raised against human rIL-2 and are highly reactive with IL-2, inhibit its biological activity, and can be used to affinity-purify IL-2 from crude culture supernatants. We are also planning to use the antibodies raised against rIL-2 or synthetic IL-2 peptides in conjunction with such peptides to study the structure-function relationship of this lymphokine. Finally, the studies are in progress to evaluate the in vivo immunostimulating potential of pure IL-2 in several experimental models characterized by deficient T-cell responses, e.g., athymic nude mice, drug (cyclophosphamide, cyclosporin A)-induced immunosuppression, and tumor-bearing mice. It is hoped that these studies will elucidate the physiological role of IL-2 in the immune responses, its immunotherapeutic potential, and the role that defects in IL-2 production and response play in various immunological diseases. (TA)

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Experimental Immunology Study Section (EI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Scripps Research Institute
La Jolla
United States
Zip Code
Knudson, Karin M; Pritzl, Curtis J; Saxena, Vikas et al. (2017) NF?B-Pim-1-Eomesodermin axis is critical for maintaining CD8 T-cell memory quality. Proc Natl Acad Sci U S A 114:E1659-E1667
Pedros, Christophe; Zhang, Yaoyang; Hu, Joyce K et al. (2016) A TRAF-like motif of the inducible costimulator ICOS controls development of germinal center TFH cells via the kinase TBK1. Nat Immunol 17:825-33
Wang, Xu-Dong; Gong, Yu; Chen, Zhi-Long et al. (2015) TCR-induced sumoylation of the kinase PKC-? controls T cell synapse organization and T cell activation. Nat Immunol 16:1195-203
Altman, Amnon; Kong, Kok-Fai (2014) Protein kinase C inhibitors for immune disorders. Drug Discov Today 19:1217-21
Kong, Kok-Fai; Fu, Guo; Zhang, Yaoyang et al. (2014) Protein kinase C-? controls CTLA-4-mediated regulatory T cell function. Nat Immunol 15:465-72
Xie, Ji-Ji; Liang, Jia-Qi; Diao, Liang-Hui et al. (2013) TNFR-associated factor 6 regulates TCR signaling via interaction with and modification of LAT adapter. J Immunol 190:4027-36
Zhang, Elizabeth Yan; Kong, Kok-Fai; Altman, Amnon (2013) The yin and yang of protein kinase C-theta (PKC?): a novel drug target for selective immunosuppression. Adv Pharmacol 66:267-312
Kong, Kok-Fai; Altman, Amnon (2013) In and out of the bull's eye: protein kinase Cs in the immunological synapse. Trends Immunol 34:234-42
Stahelin, Robert V; Kong, Kok-Fai; Raha, Sumita et al. (2012) Protein kinase C? C2 domain is a phosphotyrosine binding module that plays a key role in its activation. J Biol Chem 287:30518-28
Altman, Amnon; Kong, Kok-Fai (2012) PKC?: a new target for selective immunosuppression. Expert Rev Clin Immunol 8:205-8

Showing the most recent 10 out of 111 publications